Eagle Pharmaceuticals Inc (NASDAQ:EGRX) Director Sander A. Flaum sold 2,340 shares of the stock in a transaction on Tuesday, March 6th. The shares were sold at an average price of $53.94, for a total transaction of $126,219.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of Eagle Pharmaceuticals Inc (NASDAQ:EGRX) opened at $57.66 on Friday. The stock has a market cap of $866.16, a PE ratio of 15.92 and a beta of 1.32. The company has a current ratio of 3.99, a quick ratio of 3.88 and a debt-to-equity ratio of 0.24. Eagle Pharmaceuticals Inc has a 1 year low of $45.05 and a 1 year high of $97.15.
Eagle Pharmaceuticals (NASDAQ:EGRX) last announced its earnings results on Monday, February 26th. The specialty pharmaceutical company reported $0.84 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.00 by ($0.16). The firm had revenue of $46.80 million for the quarter, compared to analyst estimates of $53.65 million. Eagle Pharmaceuticals had a return on equity of 34.16% and a net margin of 21.94%. The company’s revenue for the quarter was down 42.3% compared to the same quarter last year. During the same quarter last year, the business earned $3.52 EPS. analysts expect that Eagle Pharmaceuticals Inc will post 2.57 earnings per share for the current fiscal year.
A number of brokerages have recently issued reports on EGRX. BidaskClub upgraded shares of Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, February 8th. ValuEngine cut shares of Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Royal Bank of Canada set a $71.00 target price on shares of Eagle Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, February 26th. Zacks Investment Research cut shares of Eagle Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Thursday, March 1st. Finally, Mizuho reiterated a “sell” rating and set a $37.00 target price on shares of Eagle Pharmaceuticals in a research report on Monday, February 26th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $62.33.
ILLEGAL ACTIVITY WARNING: “Insider Selling: Eagle Pharmaceuticals Inc (EGRX) Director Sells 2,340 Shares of Stock” was published by Ticker Report and is the property of of Ticker Report. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3253099/insider-selling-eagle-pharmaceuticals-inc-egrx-director-sells-2340-shares-of-stock.html.
About Eagle Pharmaceuticals
Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.